Life sciences

AI has huge potential to transform the end-to-end trials process. Ethical concerns and regulatory uncertainty will play a significant role in influencing how quickly the industry is able to move, and there will be the potential for new organizations to break out in this space. These will be data-rich organizations that build their platforms with their partners to generate trust and that best solve the problem of validating continually evolving models.”

Because the market is nascent, the avenues of reimbursement for DTx are non standard and evolve based on the solution.”

Many life science companies are increasingly breaking down the silos they used to be comfortable with and establishing cross-functional teams that focus on unified and holistic solutions for healthcare professionals and patients.”

The businesses that minimise waste, and maximise resource utilisation through a combination of reuse, redistribution and recycling, will lead the way in the future economy.”

Every leader should look to the smart supply chain to power the possible in their organisation – the opportunities are too considerable to ignore.”